SCI Pharmtech Inc (4119) - Net Assets
Based on the latest financial reports, SCI Pharmtech Inc (4119) has net assets worth NT$5.41 Billion TWD (≈ $170.46 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$6.95 Billion ≈ $219.12 Million USD) and total liabilities (NT$1.54 Billion ≈ $48.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 4119 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$5.41 Billion |
| % of Total Assets | 77.8% |
| Annual Growth Rate | 10.47% |
| 5-Year Change | 62.45% |
| 10-Year Change | 75.66% |
| Growth Volatility | 16.01 |
SCI Pharmtech Inc - Net Assets Trend (2002–2025)
This chart illustrates how SCI Pharmtech Inc's net assets have evolved over time, based on quarterly financial data. Check SCI Pharmtech Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Annual Net Assets for SCI Pharmtech Inc (2002–2025)
The table below shows the annual net assets of SCI Pharmtech Inc from 2002 to 2025. For live market cap and overall valuation, see SCI Pharmtech Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$5.39 Billion ≈ $169.96 Million |
-1.51% |
| 2024-12-31 | NT$5.48 Billion ≈ $172.55 Million |
+7.39% |
| 2023-12-31 | NT$5.10 Billion ≈ $160.68 Million |
+40.52% |
| 2022-12-31 | NT$3.63 Billion ≈ $114.34 Million |
+9.29% |
| 2021-12-31 | NT$3.32 Billion ≈ $104.62 Million |
-0.05% |
| 2020-12-31 | NT$3.32 Billion ≈ $104.67 Million |
-4.39% |
| 2019-12-31 | NT$3.47 Billion ≈ $109.47 Million |
+8.24% |
| 2018-12-31 | NT$3.21 Billion ≈ $101.14 Million |
+9.57% |
| 2017-12-31 | NT$2.93 Billion ≈ $92.30 Million |
-4.60% |
| 2016-12-31 | NT$3.07 Billion ≈ $96.75 Million |
+11.18% |
| 2015-12-31 | NT$2.76 Billion ≈ $87.02 Million |
+24.07% |
| 2014-12-31 | NT$2.23 Billion ≈ $70.14 Million |
+7.65% |
| 2013-12-31 | NT$2.07 Billion ≈ $65.15 Million |
+63.88% |
| 2012-12-31 | NT$1.26 Billion ≈ $39.76 Million |
+11.55% |
| 2011-12-31 | NT$1.13 Billion ≈ $35.64 Million |
0.00% |
| 2010-12-31 | NT$1.13 Billion ≈ $35.64 Million |
+9.00% |
| 2009-12-31 | NT$1.04 Billion ≈ $32.70 Million |
+10.11% |
| 2008-12-31 | NT$942.51 Million ≈ $29.69 Million |
+6.36% |
| 2007-12-31 | NT$886.14 Million ≈ $27.92 Million |
+14.05% |
| 2006-12-31 | NT$777.01 Million ≈ $24.48 Million |
+1.29% |
| 2004-12-31 | NT$767.10 Million ≈ $24.17 Million |
+2.19% |
| 2003-12-31 | NT$750.63 Million ≈ $23.65 Million |
+37.46% |
| 2002-12-31 | NT$546.06 Million ≈ $17.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SCI Pharmtech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 398.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$1.42 Billion | 26.32% |
| Common Stock | NT$1.20 Billion | 22.15% |
| Other Comprehensive Income | NT$651.43 Million | 12.08% |
| Other Components | NT$2.13 Billion | 39.45% |
| Total Equity | NT$5.39 Billion | 100.00% |
SCI Pharmtech Inc Competitors by Market Cap
The table below lists competitors of SCI Pharmtech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Creotech Quantum SA
WAR:CRQ
|
$197.88 Million |
|
A Plus Asset Advisor Co Ltd
KO:244920
|
$197.95 Million |
|
Sporting Clube de Portugal - Futebol SAD
LS:SCP
|
$197.95 Million |
|
Bell Equipment Limited
JSE:BEL
|
$198.14 Million |
|
Acme Electronics
TWO:8121
|
$197.62 Million |
|
Vertiseit AB Series B
ST:VERT-B
|
$197.41 Million |
|
Macpower CNC Machines Limited
NSE:MACPOWER
|
$197.37 Million |
|
Staude Capital Global Value Fund Ltd
AU:GVF
|
$197.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SCI Pharmtech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,476,932,000 to 5,394,482,000, a change of -82,450,000 (-1.5%).
- Net income of 107,374,000 contributed positively to equity growth.
- Dividend payments of 179,262,000 reduced retained earnings.
- Other comprehensive income increased equity by 40,528,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$107.37 Million | +1.99% |
| Dividends Paid | NT$179.26 Million | -3.32% |
| Other Comprehensive Income | NT$40.53 Million | +0.75% |
| Other Changes | NT$-51.09 Million | -0.95% |
| Total Change | NT$- | -1.51% |
Book Value vs Market Value Analysis
This analysis compares SCI Pharmtech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.91x to 1.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$13.44 | NT$52.50 | x |
| 2010-12-31 | NT$14.47 | NT$52.50 | x |
| 2011-12-31 | NT$14.47 | NT$52.50 | x |
| 2012-12-31 | NT$16.51 | NT$52.50 | x |
| 2013-12-31 | NT$19.51 | NT$52.50 | x |
| 2014-12-31 | NT$20.75 | NT$52.50 | x |
| 2015-12-31 | NT$25.58 | NT$52.50 | x |
| 2016-12-31 | NT$28.42 | NT$52.50 | x |
| 2017-12-31 | NT$27.11 | NT$52.50 | x |
| 2018-12-31 | NT$29.92 | NT$52.50 | x |
| 2019-12-31 | NT$31.58 | NT$52.50 | x |
| 2020-12-31 | NT$30.23 | NT$52.50 | x |
| 2021-12-31 | NT$30.41 | NT$52.50 | x |
| 2022-12-31 | NT$33.20 | NT$52.50 | x |
| 2023-12-31 | NT$46.53 | NT$52.50 | x |
| 2024-12-31 | NT$45.66 | NT$52.50 | x |
| 2025-12-31 | NT$45.03 | NT$52.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SCI Pharmtech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.99%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.28x
- Recent ROE (1.99%) is below the historical average (10.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 15.28% | 16.37% | 0.63x | 1.47x | NT$28.83 Million |
| 2003 | 11.62% | 16.95% | 0.60x | 1.14x | NT$12.13 Million |
| 2004 | 5.45% | 9.12% | 0.51x | 1.17x | NT$-34.93 Million |
| 2006 | 5.92% | 8.93% | 0.59x | 1.12x | NT$-31.72 Million |
| 2007 | 16.99% | 18.75% | 0.76x | 1.20x | NT$61.90 Million |
| 2008 | 16.62% | 16.56% | 0.83x | 1.20x | NT$62.35 Million |
| 2009 | 16.02% | 18.36% | 0.72x | 1.21x | NT$62.53 Million |
| 2010 | 15.14% | 17.22% | 0.66x | 1.33x | NT$58.12 Million |
| 2011 | 7.96% | 8.67% | 0.68x | 1.34x | NT$-23.10 Million |
| 2012 | 15.41% | 15.40% | 0.80x | 1.25x | NT$68.26 Million |
| 2013 | 7.73% | 12.37% | 0.42x | 1.48x | NT$-46.86 Million |
| 2014 | 11.90% | 17.75% | 0.46x | 1.45x | NT$42.22 Million |
| 2015 | 13.54% | 20.65% | 0.52x | 1.25x | NT$97.70 Million |
| 2016 | 13.58% | 21.91% | 0.54x | 1.16x | NT$109.86 Million |
| 2017 | 6.52% | 14.68% | 0.39x | 1.12x | NT$-102.00 Million |
| 2018 | 13.93% | 23.05% | 0.51x | 1.18x | NT$126.21 Million |
| 2019 | 16.44% | 24.24% | 0.58x | 1.17x | NT$223.64 Million |
| 2020 | 10.84% | 13.39% | 0.59x | 1.38x | NT$27.90 Million |
| 2021 | 1.68% | 6.44% | 0.21x | 1.26x | NT$-276.37 Million |
| 2022 | 8.51% | 34.32% | 0.18x | 1.37x | NT$-54.14 Million |
| 2023 | 5.78% | 24.48% | 0.18x | 1.31x | NT$-215.27 Million |
| 2024 | 9.76% | 35.09% | 0.21x | 1.31x | NT$-13.02 Million |
| 2025 | 1.99% | 7.99% | 0.20x | 1.28x | NT$-432.07 Million |
Industry Comparison
This section compares SCI Pharmtech Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,283,293,400
- Average return on equity (ROE) among peers: 12.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SCI Pharmtech Inc (4119) | NT$5.41 Billion | 15.28% | 0.29x | $197.67 Million |
| Grape King Bio Ltd (1707) | $7.47 Billion | 25.95% | 0.52x | $421.44 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $4.20 Billion | 8.65% | 0.52x | $319.22 Million |
| Maywufa Co Ltd (1731) | $1.69 Billion | 3.77% | 0.52x | $88.57 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.53 Billion | 2.68% | 0.13x | $468.36 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $23.78 Billion | 19.85% | 3.46x | $1.60 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $892.84 Million | 13.96% | 0.32x | $40.10 Million |
| LIWANLI Innovation Co Ltd (3054) | $1.38 Billion | 21.02% | 0.55x | $122.85 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $450.65 Million |
| TTY Biopharm Co Ltd (4105) | $8.05 Billion | 19.36% | 0.41x | $604.77 Million |
| Phytohealth Corp (4108) | $146.02 Million | 0.00% | 0.07x | $69.77 Million |
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more